Trimel Biopharma SRL, a wholly-owned subsidiary of Trimel Pharmaceuticals, has partnered with a privately-held European company to develop single dose and fixed dose combinations of a portfolio of active pharmaceutical ingredients for the treatment of a variety of respiratory disorders.
As part of this transaction, Trimel SRL's inhalation technology TriVair will be used for the development of the active pharmaceutical ingredients.
TriVair is a disposable, single unit dose, dry powder inhalation drug delivery technology platform with applications for both nasal and pulmonary dosing.
Trimel SRL will gain rights to all know-how and intellectual property developed for the applicable products for territories outside of the EU, Russia and Ukraine.
The company's development partner will be granted rights to the products developed under the agreement in these markets.
Royalties will be payable by the parties to each other in connection with revenues received by each party (or any licensees) in their respective territories in connection with any developed products developed under the agreement.
